Welcome to our dedicated page for Fulgent Genetics SEC filings (Ticker: FLGT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fulgent Genetics, Inc. (NASDAQ: FLGT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Fulgent is a technology-based company with a laboratory services business and a therapeutic development business, and its SEC reports offer detailed information on both areas. Investors can review annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K to understand how the company presents its financial condition, results of operations, and material events.
Fulgent’s earnings-related 8-K filings reference press releases that discuss revenue, core revenue, GAAP and non-GAAP income or loss, gross profit and margin, and adjusted EBITDA. These filings also describe how the company defines and reconciles non-GAAP measures to the most directly comparable GAAP metrics, and how management uses these measures to evaluate performance. For those analyzing FLGT stock, these documents are a primary source for understanding trends in the laboratory services and therapeutic development segments, as well as the company’s cash position and stock repurchase activity.
In addition to financial results, Fulgent uses Form 8-K to report other significant developments, such as preliminary clinical data from its oncology programs. For example, the company has filed an 8-K to furnish a press release describing preliminary data from a phase 2 trial of FID-007 in combination with cetuximab in recurrent or metastatic head and neck squamous cell carcinoma. Such filings provide context on the progress and risk profile of its therapeutic development pipeline.
On this page, users can track FLGT filings in near real time as they are made available through EDGAR. Stock Titan’s tools surface key forms such as 10-K for annual overviews, 10-Q for quarterly updates, and 8-K for material events, with AI-powered summaries that help explain complex sections and highlight important points. For those interested in governance, compensation, or potential insider activity, related SEC documents and forms can also be reviewed alongside the company’s broader disclosure record.
Fulgent Genetics, Inc. received an amended Schedule 13G/A (Amendment No. 4) reporting institutional ownership of its common stock. Investment entities including Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of about 3.0% of the common stock, including 939,375 shares with shared voting and dispositive power for several reporting persons and 918,503 shares for Integrated Core Strategies. The filers certify the shares were not acquired to change or influence control of Fulgent Genetics.
Fulgent Genetics Chief Scientific Officer Hanlin Gao reported a tax-related share withholding. On January 26, 2026, 1,331 shares of common stock were withheld at $27.53 per share to cover taxes from vested restricted stock units. After this, Gao directly owned 951,559 shares of Fulgent Genetics common stock.
Fulgent Genetics, Inc. President and COO Jian Xie reported a tax-related share withholding on common stock. On January 26, 2026, 4,711 shares of Fulgent Genetics common stock were withheld at $27.53 per share to cover tax obligations from the vesting of restricted stock units tied to a prior merger agreement.
After this transaction, Xie directly beneficially owns 332,038 common shares. In addition, 220,816 common shares are reported as indirectly owned through The Hsieh Family Dynasty Trust, where Xie serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics CFO Paul Kim reported a routine tax-related share withholding. On January 26, 2026, 3,004 shares of Fulgent Genetics common stock were withheld at
After this withholding, Kim beneficially owned 328,146 shares of common stock in direct form. The transaction was coded "F," indicating a tax withholding event linked to equity compensation rather than an open-market sale.
Fulgent Genetics (FLGT) filed a Form 4 reporting that Chief Executive Officer, director and 10% owner Ming Hsieh had 2,116 shares of common stock withheld on 11/23/2025 to cover tax obligations from vesting restricted stock units granted on February 23, 2023. After this withholding, he directly beneficially owns 802,165 common shares. He also has significant indirect holdings, including 7,895,115 shares held by the Dynasty Trust, 220,816 shares held by The Ming Hsieh Trust, and two 1,000-share Uniform Transfers to Minor Act accounts for which he serves as custodian.
Fulgent Genetics (FLGT) reported an insider equity transaction by its Chief Financial Officer and Treasurer, Paul Kim. On 11/23/2025, 671 shares of common stock were withheld at a price of $30 per share to cover tax obligations that arose when previously granted restricted stock units vested. After this tax withholding transaction, Paul Kim beneficially owned 333,447 shares of Fulgent Genetics common stock directly. This filing documents a routine administrative event related to equity compensation rather than an open-market purchase or sale.
Fulgent Genetics, Inc. reported an insider transaction by its President and COO on a Form 4. On 11/24/2025, the officer sold 681 shares of common stock at a weighted-average price of $30.473. The filing explains that the sale was made to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 23, 2023.
After this transaction, the officer beneficially owned 339,087 shares of Fulgent Genetics common stock directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust. The trust holdings are attributed because the officer serves on its investment committee, while disclaiming beneficial interest except for any pecuniary interest.
Fulgent Genetics (FLGT) insider transaction: the company’s Chief Scientific Officer reported a small sale of common stock tied to tax obligations. On 11/24/2025, the officer sold 535 shares of Fulgent Genetics common stock at a weighted-average price of $30.473 per share. The sale was coded as a disposition of securities in an open-market transaction.
According to the disclosure, these shares were sold solely to cover tax withholding that arose when previously granted restricted stock units vested. After this transaction, the officer reported beneficial ownership of 954,908 shares of Fulgent Genetics common stock, held directly.
Fulgent Genetics, Inc. (FLGT) president and COO reported insider transactions involving the company’s common stock. On 11/19/2025, the reporting person sold 10,000 shares of common stock at a weighted-average price of $29.0983 per share for year-end tax planning. On the same date, 10,000 shares were transferred as a gift to the James and Karena Xie Family Foundation, over which the reporting person has voting and investment power.
After these transactions, the reporting person directly owned 339,768 shares of Fulgent Genetics common stock and indirectly held 220,816 shares through The Hsieh Family Dynasty Trust. The filing reflects personal portfolio and charitable planning by a senior executive rather than changes to the company’s operations.
Fulgent Genetics (FLGT) filed its Q3 2025 10‑Q, showing higher revenue but continued losses as it invests in growth and therapeutics. Revenue rose to
The laboratory services segment generated nearly all revenue; one customer accounted for
Liquidity remained solid: cash and cash equivalents were
FAQ
What is the current stock price of Fulgent Genetics (FLGT)?
What is the market cap of Fulgent Genetics (FLGT)?
